NAFLD Gene-Edited Cell Lines for Drug Discovery

Non-alcoholic fatty liver disease (NAFLD) affects approximately 25% of the global adult population, according to the World Health Organization (WHO). It is the most common chronic liver disease, with prevalence rising due to obesity and metabolic syndrome. NAFLD encompasses a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The National Cancer Institute (NCI) reports that NAFLD-associated HCC has a 5-year survival rate of approximately 18% for advanced stages. Key risk factors include type 2 diabetes, dyslipidemia, and genetic predisposition (e.g., PNPLA3 I148M variant).

NAFLD is ideal for mechanistic studies due to its complex interplay of metabolic, inflammatory, and genetic factors. Subtypes include simple steatosis (NAFL) and NASH, each with distinct molecular signatures. Public datasets such as the GEO (Gene Expression Omnibus) and the NASH CRN provide transcriptomic and clinical data. Open questions include the drivers of NASH progression, the role of lipotoxicity, and the identification of therapeutic targets for fibrosis reversal.

• • NAFLD pathogenesis involves multiple pathways:
• • Lipotoxicity: Accumulation of free fatty acids and diacylglycerols leads to endoplasmic reticulum stress and mitochondrial dysfunction.
• • Inflammatory signaling: Activation of JNK and NF-kB pathways by lipotoxic lipids promotes hepatic inflammation.
• • Fibrotic cascade: Activation of hepatic stellate cells via TGF-beta and PDGF signaling drives collagen deposition.
• • Insulin resistance: Impaired insulin signaling in hepatocytes exacerbates de novo lipogenesis.

Data from TCGA and COSMIC databases.

• • Key signaling networks in NAFLD:
• • Insulin/IGF-1 signaling: Downstream PI3K/AKT pathway is impaired, leading to increased gluconeogenesis and lipogenesis.
• • MAPK pathway: JNK and p38 activation by lipotoxicity promotes inflammation and apoptosis.
• • PPAR signaling: PPAR-alpha and PPAR-gamma regulate lipid metabolism; dysregulation contributes to steatosis.
• • Wnt/beta-catenin: Reduced signaling in NASH promotes fibrosis and HCC progression.
• • Autophagy: Impaired autophagic flux exacerbates lipid accumulation and cellular stress.

Organoids derived from patient biopsies recapitulate steatosis and NASH features, including lipid accumulation and inflammatory responses, offering a more physiologically relevant platform for drug testing.

• • Common animal models for NAFLD:
• • Diet-induced models: Methionine-choline-deficient (MCD) diet, high-fat diet (HFD), and Western diet (high fat, fructose, cholesterol).
• • Genetic models: ob/ob (leptin-deficient), db/db (leptin receptor-deficient), and foz/foz (Alms1 mutant) mice.
• • GEMMs: Liver-specific Pten knockout, Pparg knockout, and Srebf1 transgenic mice.
• • PDX models: Patient-derived xenografts for NASH-HCC studies.

• • CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications relevant to NAFLD. Examples include:
• • PNPLA3 I148M knock-in in HepG2 or Huh-7 cells to model the common risk variant.
• • TM6SF2 E167K knock-in to study VLDL secretion defects.
• • TP53 knockout in hepatocyte lines to investigate tumor suppression in NASH-HCC.
• • PPARA knockout to examine lipid metabolism regulation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic backgrounds for functional studies, drug screening, and target validation.

• • Knockout and knock-in lines validate the role of specific genes in NAFLD pathogenesis. For example:
• • PNPLA3 knockout in HepG2 cells reduces lipid droplet size, confirming its role in triglyceride hydrolysis.
• • TM6SF2 knockout increases intracellular lipid content, validating its function in VLDL secretion.
• • MBOAT7 knockout exacerbates inflammatory cytokine release in response to fatty acid treatment.

Isogenic cell pairs (e.g., PNPLA3 wild-type vs. I148M knock-in) enable high-throughput screening for compounds that reduce steatosis or inflammation. Resistance mechanisms can be studied by exposing cells to drugs and identifying adaptive mutations via sequencing.

CRISPR-based synthetic lethality screens identify genes whose loss is lethal only in specific genetic backgrounds (e.g., PNPLA3 mutant cells). This approach can uncover novel biomarkers for NASH progression and therapeutic targets.